Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing

Tenaya Therapeutics, Inc.

Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.
R&D expenses $54.4M in FY2021 (up from $31.1M); G&A $18.4M (up from $7.8M).
Net loss $72.7M ($4.10/share) vs $38.4M ($39.50/share) in 2020.
TN-201 IND submission for MYBPC3 HCM expected H2 2022; TN-301 IND H2 2022; TN-401 IND in 2023.
Appointed Sunita Sethi (SVP Regulatory) and Naymisha Patel (SVP Quality); cGMP facility in Union City to be operational H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.